Randomized controlled study of natural interferon α as adjuvant treatment for stage II or III renal cell carcinoma

Shiro Hinotsu, Koji Kawai, Seiichiro Ozono, Tomoyasu Tsushima, Noriaki Tokuda, Koichiro Nomata, Seiji Naito, Hideyuki Akaza

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The prophylactic effect of postoperative interferon on recurrence and distant metastasis in stage II or III renal cell carcinoma is unclear. In most studies, interferon has been administered for 6 months or less. Therefore, we performed a clinical study of the efficacy of 1-year postoperative administration of natural interferon α, which is generally used in Japan. Methods: The subjects were patients diagnosed with stage II or III renal cell carcinoma who underwent radical nephrectomy. The subjects were randomly allocated to receive an intramuscular injection of natural interferon α (3 million to 6 million units) 3 times a week for 1 year or to receive follow-up observation until recurrence or metastasis occurred. Chest and abdominal CT were performed once yearly for all patients. The primary endpoint was progression-free survival. Results: From September 2001 to August 2006, a total of 107 patients were registered, but 7 subsequently withdrew from the study. Therefore, 100 patients were included in the analysis. The primary endpoint of progression-free survival did not differ significantly between the groups that received natural interferon α or follow-up observation (p = 0.456, log-rank test). However, peak hazards of progression in the interferon group were delayed for about 6-10 months compared with the observation group. Conclusion: Progression-free survival showed no improvement after administration of natural interferon α to patients with stage II or III renal cell carcinoma for 1 year after radical nephrectomy. The peak hazards of progression might be delayed by about 6 months by interferon administration.

Original languageEnglish
Pages (from-to)68-74
Number of pages7
JournalInternational Journal of Clinical Oncology
Volume18
Issue number1
DOIs
Publication statusPublished - Feb 2013
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Interferons
Disease-Free Survival
Observation
Therapeutics
Nephrectomy
Neoplasm Metastasis
Recurrence
Intramuscular Injections
Japan
Thorax

Keywords

  • Clinical trial
  • Interferon alfa
  • Metastasis
  • Progression-free survival
  • Recurrence
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Cite this

Randomized controlled study of natural interferon α as adjuvant treatment for stage II or III renal cell carcinoma. / Hinotsu, Shiro; Kawai, Koji; Ozono, Seiichiro; Tsushima, Tomoyasu; Tokuda, Noriaki; Nomata, Koichiro; Naito, Seiji; Akaza, Hideyuki.

In: International Journal of Clinical Oncology, Vol. 18, No. 1, 02.2013, p. 68-74.

Research output: Contribution to journalArticle

Hinotsu, Shiro ; Kawai, Koji ; Ozono, Seiichiro ; Tsushima, Tomoyasu ; Tokuda, Noriaki ; Nomata, Koichiro ; Naito, Seiji ; Akaza, Hideyuki. / Randomized controlled study of natural interferon α as adjuvant treatment for stage II or III renal cell carcinoma. In: International Journal of Clinical Oncology. 2013 ; Vol. 18, No. 1. pp. 68-74.
@article{6d3e3ddb49bc4326b46ae32da1c317d4,
title = "Randomized controlled study of natural interferon α as adjuvant treatment for stage II or III renal cell carcinoma",
abstract = "Background: The prophylactic effect of postoperative interferon on recurrence and distant metastasis in stage II or III renal cell carcinoma is unclear. In most studies, interferon has been administered for 6 months or less. Therefore, we performed a clinical study of the efficacy of 1-year postoperative administration of natural interferon α, which is generally used in Japan. Methods: The subjects were patients diagnosed with stage II or III renal cell carcinoma who underwent radical nephrectomy. The subjects were randomly allocated to receive an intramuscular injection of natural interferon α (3 million to 6 million units) 3 times a week for 1 year or to receive follow-up observation until recurrence or metastasis occurred. Chest and abdominal CT were performed once yearly for all patients. The primary endpoint was progression-free survival. Results: From September 2001 to August 2006, a total of 107 patients were registered, but 7 subsequently withdrew from the study. Therefore, 100 patients were included in the analysis. The primary endpoint of progression-free survival did not differ significantly between the groups that received natural interferon α or follow-up observation (p = 0.456, log-rank test). However, peak hazards of progression in the interferon group were delayed for about 6-10 months compared with the observation group. Conclusion: Progression-free survival showed no improvement after administration of natural interferon α to patients with stage II or III renal cell carcinoma for 1 year after radical nephrectomy. The peak hazards of progression might be delayed by about 6 months by interferon administration.",
keywords = "Clinical trial, Interferon alfa, Metastasis, Progression-free survival, Recurrence, Renal cell carcinoma",
author = "Shiro Hinotsu and Koji Kawai and Seiichiro Ozono and Tomoyasu Tsushima and Noriaki Tokuda and Koichiro Nomata and Seiji Naito and Hideyuki Akaza",
year = "2013",
month = "2",
doi = "10.1007/s10147-011-0345-9",
language = "English",
volume = "18",
pages = "68--74",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Randomized controlled study of natural interferon α as adjuvant treatment for stage II or III renal cell carcinoma

AU - Hinotsu, Shiro

AU - Kawai, Koji

AU - Ozono, Seiichiro

AU - Tsushima, Tomoyasu

AU - Tokuda, Noriaki

AU - Nomata, Koichiro

AU - Naito, Seiji

AU - Akaza, Hideyuki

PY - 2013/2

Y1 - 2013/2

N2 - Background: The prophylactic effect of postoperative interferon on recurrence and distant metastasis in stage II or III renal cell carcinoma is unclear. In most studies, interferon has been administered for 6 months or less. Therefore, we performed a clinical study of the efficacy of 1-year postoperative administration of natural interferon α, which is generally used in Japan. Methods: The subjects were patients diagnosed with stage II or III renal cell carcinoma who underwent radical nephrectomy. The subjects were randomly allocated to receive an intramuscular injection of natural interferon α (3 million to 6 million units) 3 times a week for 1 year or to receive follow-up observation until recurrence or metastasis occurred. Chest and abdominal CT were performed once yearly for all patients. The primary endpoint was progression-free survival. Results: From September 2001 to August 2006, a total of 107 patients were registered, but 7 subsequently withdrew from the study. Therefore, 100 patients were included in the analysis. The primary endpoint of progression-free survival did not differ significantly between the groups that received natural interferon α or follow-up observation (p = 0.456, log-rank test). However, peak hazards of progression in the interferon group were delayed for about 6-10 months compared with the observation group. Conclusion: Progression-free survival showed no improvement after administration of natural interferon α to patients with stage II or III renal cell carcinoma for 1 year after radical nephrectomy. The peak hazards of progression might be delayed by about 6 months by interferon administration.

AB - Background: The prophylactic effect of postoperative interferon on recurrence and distant metastasis in stage II or III renal cell carcinoma is unclear. In most studies, interferon has been administered for 6 months or less. Therefore, we performed a clinical study of the efficacy of 1-year postoperative administration of natural interferon α, which is generally used in Japan. Methods: The subjects were patients diagnosed with stage II or III renal cell carcinoma who underwent radical nephrectomy. The subjects were randomly allocated to receive an intramuscular injection of natural interferon α (3 million to 6 million units) 3 times a week for 1 year or to receive follow-up observation until recurrence or metastasis occurred. Chest and abdominal CT were performed once yearly for all patients. The primary endpoint was progression-free survival. Results: From September 2001 to August 2006, a total of 107 patients were registered, but 7 subsequently withdrew from the study. Therefore, 100 patients were included in the analysis. The primary endpoint of progression-free survival did not differ significantly between the groups that received natural interferon α or follow-up observation (p = 0.456, log-rank test). However, peak hazards of progression in the interferon group were delayed for about 6-10 months compared with the observation group. Conclusion: Progression-free survival showed no improvement after administration of natural interferon α to patients with stage II or III renal cell carcinoma for 1 year after radical nephrectomy. The peak hazards of progression might be delayed by about 6 months by interferon administration.

KW - Clinical trial

KW - Interferon alfa

KW - Metastasis

KW - Progression-free survival

KW - Recurrence

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84874110905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874110905&partnerID=8YFLogxK

U2 - 10.1007/s10147-011-0345-9

DO - 10.1007/s10147-011-0345-9

M3 - Article

VL - 18

SP - 68

EP - 74

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 1

ER -